Simulation of temperature and chemical weathering effect on marble rocks

Physical and mechanical properties of building stones can vary due to different degradation mechanisms caused by temperature and chemical agents. The problem of chemical and thermal weathering on marble rocks is an important issue to consider for designing building façades since it may cause sugaring, bowing, cracking and spalling. Moreover, an accurate comprehension of induced damages is required for restoration and conservation of heritage monument purposes. While thermal weathering has been widely studied in the last years, the combined effect of thermal and chemical weathering (that here is intended as the combined action of rainwater and atmospheric pollutants) is still poorly understood. In this study, no- destructive (ultrasonic pulse velocities) and destructive tests (bending tests) were performed on Carrara marble slabs in natural and after thermal (with target temperatures respectively of 50 and 90°C) and thermo-chemical treatment. Thermo-chemical treatments were performed by soaking the specimens in a 5x10-6 mol/l solution of sulphuric acid at pH=5 to simulate the acid rain behavior, at constant target temperatures, for one week. In general, for each weathering mechanism, progressive degradation of the physical and mechanical properties of marble specimens was observed. In particular, a marked drop in flexural strength, mirrored by a wide variation in P- and S-wave velocity, was found in specimens chemically treated at target temperature equal to 90 °C

STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF THE PROMOTER REGIONS OF THE NFKB2 GENE

In order to clarify the transcriptional regulation of the NFKB2 gene (lyt-10, NF-kappa Bp100), we have characterized the structure and function of its promoter regions. Based on the nucleotide sequence of cDNA clones and the 5' flanking genomic region of the NFKB2 gene, RT-PCR analysis in a number of human cell lines demonstrated the presence of two alternative noncoding first exons (Ia and Ib). Two distinct promoter regions, P1 and P2, were identified upstream of each exon, containing multiple sites of transcription initiation, as shown by RNase protection analysis. Sequence analysis of these regions showed a CAAT box upstream of exon Ia and high G-C content regions within both P1 and P2. Consensus binding sites for transcription factors, including SP1, API and putative NF-kappa B (kappa B sites), were found upstream of each exon. In particular, six kappa B sites were identified, all but one of them capable of binding NF-kappa B complexes in vitro. Transfection in HeLa cells of plasmids containing PI and P2 sequences linked to a chloramphenicol acetyltransferase reporter gene indicated that both P1 and P2 can act independently as promoters. Co-transfection of NF-kappa B effector plasmids (NF-kappa Bp5a and RelA) with a reporter gene linked to P1 and P2 showed that the NFKB2 promoter regions are regulated by NF-kappa B factors. RelA transactivates the NFKB2 promoter in a dose-dependent manner, whereas NF-kappa Bp52 acts as a repressor, indicating that the NFKB2 gene may be under the control of a negative feedback regulatory circuit

Electrophoretic variants in three Amerindian tribes: The Baniwa, Kanamari, and Central Pano of Western Brazil

Data are presented on electrophoretic variants of 25 polypeptides found in the blood serum and erythrocytes, in 812 individuals from three Amerindian tribes, the Pano, the Baniwa, and the Kanamari. Two “private polymorphisms” were encountered, of PEPB in the Pano and CAII in the Baniwa. A single example of a different PEPB variant was encountered in the Baniwa, and two possible examples of an unstable variant of HGB A 2 in the Kanamari. In addition, the well-known A variant of ACP 1 , the Duarte variant of GALT, the 2 variant of Hp and the 2 variant of PGM 1 occurred in polymorphic proportions in all three tribes, and the TF D Chi variant was present as a polymorphism in the Baniwa. These data have recently been incorporated into a treatment which concludes that the eight electrophoretically-defined “private polymorphisms” thus far encountered in Amerindian tribes can be explained by a mutation pressure of 0.7 × 10 −5 /locus/generation on the assumption of neutrality of the phenotypes in question (Neel and Thompson, '78).Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/37590/1/1330500212_ftp.pd

The VICI-trial: high frequency oscillation versus conventional mechanical ventilation in newborns with congenital diaphragmatic hernia: an international multicentre randomized controlled trial

Background: Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly of the diaphragm resulting in pulmonary hypoplasia and pulmonary hypertension. It is associated with a high risk of mortality and pulmonary morbidity. Previous retrospective studies have reported high frequency oscillatory ventilation (HFO) to reduce pulmonary morbidity in infants with CDH, while others indicated HFO to be associated with worse outcome. We therefore aimed to develop a randomized controlled trial to compare initial ventilatory treatment with high-frequency oscillation and conventional ventilation in infants with CDH.Methods/design: This trial is designed as a multicentre trial in which 400 infants (200 in each arm) will be included. Primary outcome measures are BPD, described as oxygen dependency by day 28 according to the definition of Jobe and Bancalari, and/or mortality by day 28. All liveborn infants with CDH born at a gestational age of over 34 weeks and no other severe congenital anomalies are eligible for inclusion. Parental informed consent is asked antenatally and the allocated ventilation mode starts within two hours after birth. Laboratory samples of blood, urine and tracheal aspirate are taken at the first day of life, day 3, day 7, day 14 and day 28 to evaluate laboratory markers for ventilator-induced lung injury and pulmonary hypertension.Discussion: To date, randomized clinical trials are lacking in the field of CDH. The VICI-trial, as the first randomized clinical trial in the field of CDH, may provide further insight in ventilation strategies in CDH patient. This may hopefully prevent mortality and morbidity.Trial registration: Netherlands Trial Register (NTR): NTR1310

Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: A retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database

Aims Oral glucose-lowering medications are associated with excess risk of heart failure (HF). Given the absence of comparative data among drug classes, we performed a retrospective study in 32 Health Services of 16 Italian regions accounting for a population of 18 million individuals, to assess the association between HF risk and use of sulphonylureas, DPP-4i, and glitazones. Methods and results We extracted data on patients with type 2 diabetes who initiated treatment with DPP-4i, thiazolidinediones, or sulphonylureas alone or in combination with metformin during an accrual time of 2 years. The endpoint was hospitalization for HF (HHF) occurring after the first 6 months of therapy, and the observation was extended for up to 4 years. A total of 127 555 patients were included, of whom 14.3% were on DPP-4i, 72.5% on sulphonylurea, 13.2% on thiazolidinediones, with average 70.7% being on metformin as combination therapy. Patients in the three groups differed significantly for baseline characteristics: age, sex, Charlson index, concurrent medications, and previous cardiovascular events. During an average 2.6-year follow-up, after adjusting for measured confounders, use of DPP-4i was associated with a reduced risk of HHF compared with sulphonylureas [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.62-0.97; P = 0.026]. After propensity matching, the analysis was restricted to 39 465 patients, and the use of DPP-4i was still associated with a lower risk of HHF (HR 0.70; 95% CI 0.52-0.94; P = 0.018). Conclusion In a very large observational study, the use of DPP-4i was associated with a reduced risk of HHF when compared with sulphonylureas

Can we improve outcome of congenital diaphragmatic hernia?

This review gives an overview of the disease spectrum of congenital diaphragmatic hernia (CDH). Etiological factors, prenatal predictors of survival, new treatment strategies and long-term morbidity are described. Early recognition of problems and improvement of treatment strategies in CDH patients may increase survival and prevent secondary morbidity. Multidisciplinary healthcare is necessary to improve healthcare for CDH patients. Absence of international therapy guidelines, lack of evidence of many therapeutic modalities and the relative low number of CDH patients calls for cooperation between centers with an expertise in the treatment of CDH patients. The international CDH Euro-Consortium is an example of such a collaborative network, which enhances exchange of knowledge, future research and development of treatment protocols

Debris flow risk mitigation by the means of rigid and flexible barriers – experimental tests and impact analysis

The impact of a debris flow on a structure can have disastrous effects because of the enormous destructive potential of this type of phenomenon. Although the introduction of risk mitigation structures such as the Sabo Dam, the filter dam and more recently flexible barriers is usual, there are very few methods that are universally recognized for the safe design of such structures. This study presents the results of experimental tests, conducted with the use of a specifically created flume, in order to obtain detailed knowledge of the mechanical aspects, and to analyze the dynamics of the impact of a debris flow on different types of structures. The analyses of the tests, together with the calculation of the thrust caused by the flow, have made it possible to analyze the dynamics of the impact, which has shown differing effects, on the basis of the type of barrier that has been installed